Last reviewed · How we verify
Prolensa 0.07% Ophthalmic Solution
Prolensa is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain in the eye.
Prolensa is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce inflammation and pain in the eye. Used for Postoperative inflammation and pain following cataract surgery, Ocular itching associated with allergic conjunctivitis.
At a glance
| Generic name | Prolensa 0.07% Ophthalmic Solution |
|---|---|
| Sponsor | Nicole Fram M.D. |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bromfenac, the active ingredient in Prolensa, is a topical ophthalmic NSAID that works by inhibiting COX-1 and COX-2 enzymes, thereby reducing the production of prostaglandins in ocular tissues. This mechanism reduces inflammation, pain, and photophobia associated with ocular surgery and other inflammatory conditions of the eye. The 0.07% formulation is optimized for topical ocular delivery.
Approved indications
- Postoperative inflammation and pain following cataract surgery
- Ocular itching associated with allergic conjunctivitis
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Corneal erosion or keratitis
- Headache
Key clinical trials
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial (PHASE4)
- Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (NA)
- Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prolensa 0.07% Ophthalmic Solution CI brief — competitive landscape report
- Prolensa 0.07% Ophthalmic Solution updates RSS · CI watch RSS
- Nicole Fram M.D. portfolio CI